## Highlights ## Migraine treatment with erenumab (70 mg initially, later increased to 140 mg) showed sustained efficacy and safety for over five years. Erenumab showed improved safety and a reduced incidence of adverse events, including immunogenic reactions.## Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) receptor pathway have shown significant reductions in migraine frequency and improved health-related quality of life in multiple 12- to 24-week double-blind trials.
A 5-year open-label treatment phase (OLTP) following completion of a 12-week double-blind treatment phase (DBTP) trial was conducted to evaluate the extended efficacy and safety of erenumab (an anti-CGRP receptor monoclonal antibody) in treating migraine for five years. Here's a Journal Watch that discusses the study “ Long-term efficacy and safety of erenumab in migraine prevention:…
